KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Operating Leases (2021 - 2025)

Bionano Genomics' Operating Leases history spans 5 years, with the latest figure at $2.6 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 29.49% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $2.6 million, down 29.49%, while the annual FY2024 figure was $145000.0, 95.96% down from the prior year.
  • Operating Leases for Q3 2025 was $2.6 million at Bionano Genomics, down from $4.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $7.2 million in Q1 2022 and bottomed at $145000.0 in Q4 2024.
  • The 5-year median for Operating Leases is $4.6 million (2023), against an average of $4.3 million.
  • The largest annual shift saw Operating Leases rose 4.08% in 2022 before it plummeted 95.96% in 2024.
  • A 5-year view of Operating Leases shows it stood at $5.3 million in 2021, then rose by 4.08% to $5.5 million in 2022, then tumbled by 34.77% to $3.6 million in 2023, then tumbled by 95.96% to $145000.0 in 2024, then surged by 1692.41% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Operating Leases are $2.6 million (Q3 2025), $4.1 million (Q2 2025), and $145000.0 (Q4 2024).